Bambusa TherapeuticsNew filing
Bambusa Therapeutics files for an IPO
Bambusa Therapeutics files for an IPO (October 9, 2026).
Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation.
Offering details
- Exchange
- Nasdaq Global Select Market
- Proposed ticker
- BBTX